Skip to main content

Progyny, Inc. (PGNY)

NASDAQ: PGNY · IEX Real-Time Price · USD
55.41
-0.58 (-1.04%)
After-hours:Oct 15, 2021 7:18 PM EDT
55.99
-2.30 (-3.95%)
At close: Oct 15, 4:00 PM
Market Cap5.01B
Revenue (ttm)450.01M
Net Income (ttm)78.11M
Shares Out88.17M
EPS (ttm)0.78
PE Ratio71.87
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume736,010
Open59.25
Previous Close58.29
Day's Range55.78 - 59.25
52-Week Range23.56 - 66.61
Betan/a
AnalystsStrong Buy
Price Target70.20 (+25.4%)
Est. Earnings DateNov 4, 2021

About PGNY

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimburseme...

IndustryHealth Care Providers & Services
IPO DateOct 25, 2019
Employees210
Stock ExchangeNASDAQ
Ticker SymbolPGNY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for Progyny stock is "Strong Buy." The 12-month stock price forecast is 70.20, which is an increase of 25.38% from the latest price.

Price Target
$70.20
(25.38% upside)
Analyst Consensus: Strong Buy

News

3 Innovative Growth Stocks That'll Make You Richer Through 2025

Their products are better than those of their rivals, and their leads are increasing.

Other symbols:DXCMORGO
1 week ago - The Motley Fool

Despite A 25% Rise In A Month Progyny Stock May Continue To See Higher Levels

The stock price of Progyny (NASDAQ: PGNY), a benefits management company that specializes in fertility and family building benefits solutions, has seen a rise of around 25% over the last month (twenty-o...

4 weeks ago - Forbes

Progyny, Inc. to Present at the BofA Global Healthcare Conference

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, to...

1 month ago - GlobeNewsWire

Why This Ultra-High-Growth Healthcare Stock Is a Buy

When a founder-led company is profitably chasing a huge market and having early success, the stock is worth a closer look.

1 month ago - The Motley Fool

5 Medical Services Stocks Countering Industry Headwinds

The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, PGNY, SGRY, MODV, and AGTI are set to gain the most.

Other symbols:AGTIHQYMODVSGRY
1 month ago - Zacks Investment Research

Progyny, Inc. to Present at the BofA Securities SMID Cap 2H21 Ideas Conference

NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, tod...

2 months ago - GlobeNewsWire

Progyny's Stock Is Getting Hammered On Mixed Q2 Earnings; Outlook Lagging Street Consensus

Progyny Inc (NASDAQ: PGNY) reported Q2 EPS of $0.19, a turnaround from EPS loss of $(0.01) a year ago, edging out analysts' average expectation of $0.08. Sales almost doubled to $128.6 million but misse...

2 months ago - Benzinga

Progyny (PGNY) Beats Q2 Earnings Estimates

Progyny (PGNY) delivered earnings and revenue surprises of 111.11% and -0.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Progyny: Q2 Earnings Insights

Shares of Progyny (NASDAQ:PGNY) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 1050.00% over the past year to $0.19, which beat the es...

2 months ago - Benzinga

Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth

Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Progyny, Inc. Announces Details for Its Second Quarter 2021 Results Report

NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, wil...

2 months ago - GlobeNewsWire

Progyny (PGNY) Moves to Strong Buy: Rationale Behind the Upgrade

Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

2 months ago - Zacks Investment Research

4 Stocks With High Net Income Ratio to Scoop Up

APPS, QFIN, PGNY, and SSP have qualified the screen for high net income ratio stocks.

Other symbols:APPSQFINSSP
2 months ago - Zacks Investment Research

Progyny (PGNY) Sees Hammer Chart Pattern: Time to Buy?

Progyny (PGNY) has been struggling lately, but the selling pressure may be coming to an end soon.

3 months ago - Zacks Investment Research

7 Must-See Stock Charts That Spell More Upside

Despite the strong rally in U.S. stocks, there has been volatility too. Here are the seven best stock charts that could spell more upside.

Other symbols:AAPLAMZNDIAHDSBUX
3 months ago - InvestorPlace

I'm selling Progyny this week [June 24th], and this is why!

Progyny, Inc (NASDAQ: PGNY) shares have advanced more than  40% since the beginning of January 2021, and the current share price stands around $59. Progyny expects adjusted EBITDA between $70 million to...

3 months ago - Invezz

Here's Why Progyny (PGNY) is a Great Momentum Stock to Buy

Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.

3 months ago - Zacks Investment Research

Progyny's (PGNY) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Progyny, Inc. (PGNY)

4 months ago - Zacks Investment Research

Progyny, Inc. to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, tod...

4 months ago - GlobeNewsWire

Earnings Estimates Moving Higher for Progyny (PGNY): Time to Buy?

Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

4 months ago - Zacks Investment Research

Here's What Could Help Progyny (PGNY) Maintain Its Recent Price Strength

Progyny (PGNY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "R...

4 months ago - Zacks Investment Research

Largest Research Study on Decision Making of Single or Coupled Intended Fathers Selected for Presentation at 2021 ACO...

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, alon...

4 months ago - GlobeNewsWire

Welltok Welcomes Maven and Progyny to its Connect Ecosystem Family

DENVER, May 19, 2021 /PRNewswire/ -- Family planning and fertility benefits are becoming more mainstream with employers seeking to demonstrate inclusivity and attract or retain talent. As women become m...

4 months ago - PRNewsWire

Progyny, Inc. to Present at the BofA Securities 2021 Health Care Conference

NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, toda...

5 months ago - GlobeNewsWire

Progyny (PGNY) Q1 Earnings and Revenues Surpass Estimates

Progyny (PGNY) delivered earnings and revenue surprises of 87.50% and 0.46%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research